Celling Biosciences Received CE Mark Approval for ART PRP and ART BMC Systems


Celling Biosciences ART BMC Plus

With an aging global population and rising dangers of opioid addiction and complications, demand for platelet-rich plasma and bone marrow concentrate based treatments has been steadily rising in the United States. According to the Global Regenerative Medicine Market 2016-2020 report, the specialty of regenerative medicine is forecasted to grow at a CAGR of 20.7%. Hank Brown, Celling Biosciences Executive Vice President of Sales, stated, “The CE Mark approval allows the company to respond to the growing opportunity in international markets, particularly within Europe, so this achievement is an important milestone in the…



Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *